An observational study in Sudden Cardiac Death, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by China National Center for Cardiovascular Diseases · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Death, Sudden, Cardiac with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Death, Sudden, Cardiac · China.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, this one is the 12th largest by planned enrollment of the 15 observational ones that give a count, is one of 2 that started in 2026, is one of 15 observational ones, and was the 17th registered.
364 studies on the registry are indexed under Death, Sudden, Cardiac; 84 are open to participants now.
Browse Death, Sudden, Cardiac studies →9 of the 19 studies in Death, Sudden, Cardiac with a site in China are open now. Recruiting first, the newest first:
Beijing Anzhen Hospital · Sites in China
Ages 18–80
Chensheng Pan · Sites in China
Ages 18+
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 16–90 · Healthy volunteers
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 63 Death, Sudden, Cardiac studies recruiting now, 42 (67%) set no upper age limit and 11 (17%) stop at 75 or younger; 22 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 421 is close to the median of 450 across 203 observational studies indexed under Death, Sudden, Cardiac.
Median enrollment 342 across the 4 interventional studies, 1,491 across the 15 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 19 have an industry lead sponsor. The 10 most frequent:
China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.
China National Center for Cardiovascular Diseases has 2 studies filed under Death, Sudden, Cardiac — fewer than ten, so there is no comparison to draw.
2 of the studies in Death, Sudden, Cardiac with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856993The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEarly Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death | 2026-12-31 |
| NCT07476456China National Center for Cardiovascular DiseasesSkeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Death, Sudden, Cardiac with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is designed as a prospective, single-center, observational cohort study (the SMART-SCD Study, full name: Skeletal Muscle Multi-omics Analysis and Risk Tailoring in Sudden Cardiac Death), which enrolls high-risk populations meeting the criteria for implantable cardioverter defibrillator (ICD) implantation.
The research focuses on the mechanistic association between skeletal muscle metabolic disorders and ventricular arrhythmia (VA) as well as sudden cardiac death (SCD), and aims to construct a "muscle-heart crosstalk" risk early warning system through integration of multimodal skeletal muscle data. We will systematically collect the following data:
Baseline handgrip strength measurement (Biomi-h500+X5); Functional diagnosis and phenotyping of sarcopenia conducted via the InBody 270 body composition analyzer; Non-contrast chest and abdominal computed tomography (CT) images (to extract novel imaging phenotypes including skeletal muscle density at the T12 vertebra level, intermuscular adipose tissue, subcutaneous adipose tissue, etc.); Serum biomarkers (GDF-8, Irisin, IL-6); Metabolomics data of skeletal muscle tissue from the ICD pocket (lipid/energy metabolism profiles detected via the UPLC-QTOF/MS platform); Ambulatory electrocardiographic data. All treatment and intervention regimens for patients will be independently formulated by clinicians in accordance with clinical guidelines, and the study itself does not involve any intervention measures. Prospective follow-up will be conducted at 3/6/12 months after ICD implantation. The primary endpoint is composite ventricular arrhythmia events (including SCD, appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia/ventricular fibrillation), and the secondary endpoint is all-cause mortality.
Through the above prospective cohort study, we will integrate multimodal data including novel CT imaging phenotypes of skeletal muscle, metabolomics profiles and functional phenotyping of sarcopenia using artificial intelligence techniques, so as to construct a precision prediction model for SCD, screen novel CT imaging phenotypes of sarcopenia and myogenic metabolites, and finally establish a generalizable SCD risk assessment tool and individualized intervention strategies.
Study Population Study subjects are patients receiving implantable cardioverter defibrillator (ICD) implantation at [Name of Hospital] who meet all inclusion criteria and do not meet any of the exclusion criteria.
Inclusion Criteria:
Undergoing first-time ICD implantation (including cardiac resynchronization therapy defibrillator, CRT-D implantation); Completed multi-dimensional sarcopenia assessment at baseline; Willing to receive prospective follow-up and signed the informed consent form (ICF).
Exclusion Criteria:
History of valvular heart disease (e.g., mitral stenosis, history of heart valve replacement or valvuloplasty, etc.); Implanted ICD type is subcutaneous ICD (S-ICD) or extra-vascular ICD (EV-ICD); Concomitant comorbidities affecting muscle metabolism, such as malignant tumors, severe liver or kidney disease, etc.
Study Duration Enrollment period: Planned to complete enrollment of all subjects within 12 months after study initiation.
Total study duration: Approximately 2 years, broken down as follows: preparation and finalization of clinical trial documents (including study protocol, investigator's brochure, informed consent form, case report form) takes \~2 months; ethical review approval takes \~3 months; enrollment period is 9 months; follow-up period is 12 months; data management, statistical analysis and report writing take \~2-3 months.
Skeletal Muscle (Sarcopenia) Assessment Indicators Routine assessment: Muscle strength is measured using a handgrip dynamometer from Biometrics Ltd., UK (Biomi-h500+X5). Skeletal muscle mass is measured using a multi-frequency body composition analyzer (InBody 270, Biospace Co., Ltd., Korea) in the Rehabilitation Center of [Name of Hospital]. Sarcopenia diagnosis and phenotyping are performed combining the above two indicators.
Imaging phenotypes: Based on preoperative non-contrast chest and abdominal computed tomography (CT) images, muscle imaging features at the level of the 12th thoracic vertebra (T12) are collected, including area and density of subcutaneous adipose tissue (SAT), area and density of intermuscular adipose tissue (IMAT), and skeletal muscle density (SMD), etc.
**Biomarkers: Baseline blood and urine samples are collected to analyze sarcopenia-related factors including growth differentiation factor 8 (GDF-8), myokine irisin, and interleukin-6 (IL-6).
Metabolomics analysis: Approximately 20 mg of skeletal muscle tissue at the ICD pocket site is collected synchronously during ICD implantation for metabolomics analysis. Subjects are divided into 4 groups: sarcopenia+VA, non-sarcopenia+VA, sarcopenia+non-VA, non-sarcopenia+non-VA. Targeted detection of myogenic metabolites will be performed: we plan to enroll 30 subjects per group to explore differential metabolites in the exploratory phase, then expand the sample size for validation. The ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS) platform will be used to focus on detecting abnormalities in lipid and energy metabolism.
Follow-up content:
Primary endpoint: Composite ventricular arrhythmia (VA) events, including sudden cardiac death (SCD), appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia (VT)/ventricular fibrillation (VF).
Secondary endpoint: All-cause mortality.
patients receiving implantable cardioverter defibrillator (ICD) implantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composite ventricular arrhythmia (VA) events
including sudden cardiac death (SCD), appropriate ICD therapy documented by the device, and hemodynamically unstable ventricular tachycardia (VT)/ventricular fibrillation (VF)
Time frame: 12 months
All-cause mortality
All deaths caused by various causes
Time frame: 12 months
Plan to share: Undecided — The datasets generated and analysed during the current study can be found at Fuwai Hospital but not publicly available due to related regulations. Data and materials are however available from the authors upon reasonable request and with permission of research group.
Start is estimated for Mar 2026; primary completion for Jun 2027, 15 months later.
Of 70 non-industry observational studies under Death, Sudden, Cardiac, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 42. This study's planned 15 months is below that.
Counting every sponsor, half of 86 studies reached it within 63 months; a quarter within 40.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China National Center for Cardiovascular Diseases →